AtriCure Inc. recently held its First Quarter 2025 Earnings Conference Call, providing insights into the company's performance and future outlook. The event featured key speakers including Marissa Bych from the Gilmartin Group, Michael Carrel, President and CEO of AtriCure Inc., and Angela Wirick, Chief Financial Officer. Analysts from various financial institutions such as Canaccord Genuity, Piper Sandler, and JPMorgan participated in the call. During the conference, Michael Carrel highlighted the company's strong performance, stating, "Our first quarter performance reflects the strength of our broad platform of products and continued focus of our team on expanding patient treatment worldwide." AtriCure reported a total revenue of $124 million, marking a 14% growth, driven by their pain management segment. Angela Wirick emphasized the company's operational strategy, noting that AtriCure's guidance for 2025 takes into account "the potential modest impacts based on current information," while expressing confidence in their U.S.-based production and majority sourcing from domestic suppliers. The management reiterated the importance of their product and therapy innovation and the continuous financial and operational progress expected throughout the year. The full transcript can be accessed through the link below.